Cara Janusz to Vaccination
This is a "connection" page, showing publications Cara Janusz has written about Vaccination.
Connection Strength
3.280
-
Janusz CB, Mutua MK, Wagner AL, Boulton ML. New Vaccine Introduction and Childhood Vaccination Timeliness in Two Urban, Informal Settlements in Nairobi, Kenya. Am J Trop Med Hyg. 2021 May 17; 105(1):245-253.
Score: 0.628
-
Aguilar IB, Mendoza LO, García O, Díaz I, Figueroa J, Duarte RM, Perdomo G, Garcia AG, Janusz CB. Cost-effectiveness analysis of the introduction of the human papillomavirus vaccine in Honduras. Vaccine. 2015 May 07; 33 Suppl 1:A167-73.
Score: 0.414
-
Jauregui B, Garcia AG, Bess Janusz C, Blau J, Munier A, Atherly D, Mvundura M, Hajjeh R, Lopman B, Clark AD, Baxter L, Hutubessy R, de Quadros C, Andrus JK. Evidence-based decision-making for vaccine introductions: Overview of the ProVac International Working Group's experience. Vaccine. 2015 May 07; 33 Suppl 1(0 1):A28-33.
Score: 0.414
-
Janusz CB, Castañeda-Orjuela C, Molina Aguilera IB, Felix Garcia AG, Mendoza L, Díaz IY, Resch SC. Examining the cost of delivering routine immunization in Honduras. Vaccine. 2015 May 07; 33 Suppl 1:A53-9.
Score: 0.414
-
Prosser LA, Wallace M, Rose AM, Mercon K, Janusz CB, Gebremariam A, Hutton DW, Leidner AJ, Zhou F, Ortega-Sanchez IR, Moulia D, Link-Gelles R, Saydah S, Shah M, Pike J. Cost-Effectiveness of 2023-2024 COVID-19 Vaccination in US Adults. JAMA Netw Open. 2025 Aug 01; 8(8):e2523688.
Score: 0.210
-
Prosser LA, Perroud J, Chung GS, Gebremariam A, Janusz CB, Mercon K, Rose AM, Avanceña ALV, Kim DeLuca E, Hutton DW. The cost-effectiveness of vaccination against COVID-19 illness during the initial year of vaccination. Vaccine. 2025 Feb 27; 48:126725.
Score: 0.203
-
Janusz CB, Frye M, Mutua MK, Wagner AL, Banerjee M, Boulton ML. Vaccine Delay and Its Association With Undervaccination in Children in Sub-Saharan Africa. Am J Prev Med. 2021 Jan; 60(1 Suppl 1):S53-S64.
Score: 0.152
-
Janusz CB, Wagner AL, Masters NB, Ding Y, Zhang Y, Hutton DW, Boulton ML. Measles vaccination of young infants in China: A cost-effectiveness analysis. Vaccine. 2020 Jun 15; 38(29):4616-4624.
Score: 0.147
-
Mutua MK, Mohamed SF, Kimani-Murage EW, Kiarie L, Janusz CB, Aaby P, Fisker AB, Echoka E, Ravn H. Complete and on-time routine childhood immunisation: determinants and association with severe morbidity in urban informal settlements, Nairobi, Kenya. Ann Hum Biol. 2020 Mar; 47(2):132-141.
Score: 0.144
-
Kieninger MP, Caballero EG, Sosa AA, Amarilla CT, Jáuregui B, Janusz CB, Clark AD, Castellanos RM. Cost-effectiveness analysis of pneumococcal conjugate vaccine introduction in Paraguay. Vaccine. 2015 May 07; 33 Suppl 1:A143-53.
Score: 0.103
-
Mezones-Holguin E, Canelo-Aybar C, Clark AD, Janusz CB, Jaúregui B, Escobedo-Palza S, Hernandez AV, Vega-Porras D, González M, Fiestas F, Toledo W, Michel F, Suárez VJ. Cost-effectiveness analysis of 10- and 13-valent pneumococcal conjugate vaccines in Peru. Vaccine. 2015 May 07; 33 Suppl 1:A154-66.
Score: 0.103
-
Walwyn L, Janusz CB, Clark AD, Prieto E, Waight E, Largaespada N. Cost-effectiveness of HPV vaccination in Belize. Vaccine. 2015 May 07; 33 Suppl 1:A174-81.
Score: 0.103
-
Jauregui B, Janusz CB, Clark AD, Sinha A, Garcia AG, Resch S, Toscano CM, Sanderson C, Andrus JK. ProVac Global Initiative: a vision shaped by ten years of supporting evidence-based policy decisions. Vaccine. 2015 May 07; 33 Suppl 1:A21-7.
Score: 0.103
-
Valdés W, Janusz CB, Molina Aguilera IB, Mendoza L, Díaz IY, Resch S. Tracking financial flows for immunization in Honduras. Vaccine. 2015 May 07; 33 Suppl 1:A85-92.
Score: 0.103
-
Yeung KHT, Lin SL, Clark A, McGhee SM, Janusz CB, Atherly D, Chan KC, Nelson EAS. Economic evaluation of the introduction of rotavirus vaccine in Hong Kong. Vaccine. 2021 Jan 03; 39(1):45-58.
Score: 0.038